Studies have shown that active fund managers routinely underperform the S&P500 index*​

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR)

XFOR Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-13.20%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
130.10%

XFOR Stock Analysis

XFOR PE Ratio:

XFOR PEG Ratio: Not Available

XFOR Forward EPS Growth (12 month): 0.00%

XFOR PS Ratio: 41.5

XFOR PSG Ratio: 37.7

XFOR Forward Revenue Growth (12 month): 1.10%

XFOR Articles

No data was found